Kuliah dr. Elvioza

What is the primary pathophysiological mechanism behind polyp formation in PCV?

• Autoimmune inflammation of the choriocapillaris

• Acute subretinal hemorrhage

• Venous stasis in vortex veins with pachyvessel dilation

• Photoreceptor degeneration due to oxidative stress

Which imaging modality remains the gold standard for definitive diagnosis of PCV?

• Fundus autofluorescence

• Optical coherence tomography (OCT)

• Fluorescein angiography (FA)

• Indocyanine green angiography (ICGA)

According to the APOIS criteria, which of the following is a major OCT feature suggestive of PCV?

• Retinal pigment epithelial mottling

• Subretinal hyperreflective exudation

• Sharp-peaked pigment epithelial detachment (PED)

• Flat irregular RPE elevation

Which anti-VEGF agent targets VEGF-A, VEGF-B, and placental growth factor (PlGF)?

• Ranibizumab

• Bevacizumab

• Aflibercept

• Brolucizumab

In the PLANET study, what proportion of patients achieved polyp inactivation with aflibercept monotherapy?

• 30%

• 50%

• 85%

• 100%

What is the primary safety concern associated with brolucizumab therapy in PCV based on HAWK trial data?

• Progressive nuclear cataract

• Ocular vasculitis and intraocular inflammation (IOI)

• Hypotony

• Subretinal fibrosis

What is the purpose of the 'Treat-and-Extend' regimen in PCV management?

• To improve adherence to oral medications

• To avoid BVN detection

• To reduce injection burden while maintaining efficacy

• To detect early hemorrhage

According to the EVEREST I trial, which treatment group achieved the highest polyp regression rate?

• Ranibizumab monotherapy

• Photodynamic therapy (PDT) monotherapy

• PDT combined with ranibizumab

• Aflibercept monotherapy

Why is polyp detection more limited in OCTA compared to BVN in PCV patients?

• Polyps exhibit turbulent, slow blood flow

• Polyps show rapid pulsation that confuses the algorithm

• BVN has higher optical reflectivity

• Polyps do not absorb visible light

What is the most appropriate current indication for combining anti-VEGF with PDT in PCV management?

• All hemorrhagic PCV cases

• Type A PCV

• Large, active, or treatment-resistant polyps

• Young patients with thin choroids